Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer. (2021). Biomolecules and Biomedicine, 21(2), 198-207. https://doi.org/10.17305/bjbms.2020.4746